Possibility of Predicting Serotonin Transporter Occupancy From the In Vitro Inhibition Constant for Serotonin Transporter, the Clinically Relevant Plasma Concentration of Unbound Drugs, and Their Profiles for Substrates of Transporters.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Pharmacy and Science

• Publication date

  2017-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.xphs.2017.05.007PMID 28501470
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prediction of CNS occupancy of dopamine D2 receptor based on systemic exposure and in vitro experiments.

  2016cited by this paper
• Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients

  2014cited by this paper
• ABCB1 C3435T polymorphism is associated with susceptibility to major depression, but not with a clinical response to citalopram in a Turkish population

  2014cited by this paper
• Transport characteristics of tramadol in the blood-brain barrier.

  2014cited by this paper
• Quantitative Investigation of the Brain-to-Cerebrospinal Fluid Unbound Drug Concentration Ratio under Steady-State Conditions in Rats Using a Pharmacokinetic Model and Scaling Factors for Active Efflux Transporters

  2014cited by this paper
• Proton-coupled organic cation antiporter-mediated uptake of apomorphine enantiomers in human brain capillary endothelial cell line hCMEC/D3.

  2014cited by this paper
• Use of Cassette Dosing Approach to Examine the Effects of P-Glycoprotein on the Brain and Cerebrospinal Fluid Concentrations in Wild-Type and P-Glycoprotein Knockout Rats

  2014cited by this paper
• Translational PET imaging research.

  2014cited by this paper
• Functional expression of a proton-coupled organic cation (H+/OC) antiporter in human brain capillary endothelial cell line hCMEC/D3, a human blood–brain barrier model

  2013cited by this paper
• Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment.

  2013cited by this paper
• P-glycoprotein Inhibition Increases the Brain Distribution and Antidepressant-Like Activity of Escitalopram in Rodents

  2013cited by this paper
• Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety.

  2013cited by this paper
• Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [(11)C]DASB and (S,S)-[(18)F]FMeNER-D(2).

  2013cited by this paper
• Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability.

  2013cited by this paper
• Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor.

  2013cited by this paper
• A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.

  2013cited by this paper
• Hydrophilic anti-migraine triptans are substrates for OATP1A2, a transporter expressed at human blood-brain barrier

  2012cited by this paper
• Use of the Cassette-Dosing Approach to Assess Brain Penetration in Drug Discovery

  2012cited by this paper
• Species Comparison of In Vivo P-Glycoprotein-Mediated Brain Efflux Using mdr1a-Deficient Rats and Mice

  2012cited by this paper
• ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression

  2012cited by this paper
• Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model

  2011cited by this paper
• Pharmacokinetics of Venlafaxine Extended Release 75 mg and Desvenlafaxine 50 mg in Healthy CYP2D6 Extensive and Poor Metabolizers

  2011cited by this paper
• Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo.

  2011cited by this paper
• Quantitative Evaluation of the Impact of Active Efflux by P-Glycoprotein and Breast Cancer Resistance Protein at the Blood-Brain Barrier on the Predictability of the Unbound Concentrations of Drugs in the Brain Using Cerebrospinal Fluid Concentration as a Surrogate

  2011cited by this paper
• ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment

  2010cited by this paper
• Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein.

  2010cited by this paper
• Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.

  2009cited by this paper
• Unbound Brain Concentration Determines Receptor Occupancy: A Correlation of Drug Concentration and Brain Serotonin and Dopamine Reuptake Transporter Occupancy for Eighteen Compounds in Rats

  2009cited by this paper
• Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study.

  2008cited by this paper
• In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System

  2008cited by this paper
• Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression.

  2008cited by this paper
• MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression.

  2008cited by this paper
• Antidepressants Targeting the Serotonin Reuptake Transporter Act via a Competitive Mechanism

  2008cited by this paper
• Pharmacokinetic Genes Do Not Influence Response or Tolerance to Citalopram in the STAR*D Sample

  2008cited by this paper
• ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.

  2008cited by this paper
• CYP2D6 and ABCB1 Genetic Variability: Influence on Paroxetine Plasma Level and Therapeutic Response

  2008cited by this paper
• Identification of influx transporter for the quinolone antibacterial agent levofloxacin.

  2007cited by this paper
• Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study

  2007cited by this paper
• Effect of Breast Cancer Resistance Protein (Bcrp/Abcg2) on the Disposition of Phytoestrogens

  2007cited by this paper
• Contribution of Carrier-Mediated Transport Systems to the Blood–Brain Barrier as a Supporting and Protecting Interface for the Brain; Importance for CNS Drug Discovery and Development

  2007cited by this paper
• Interaction of Methotrexate with Organic-Anion Transporting Polypeptide 1A2 and Its Genetic Variants

  2006cited by this paper
• A dose-finding study of duloxetine based on serotonin transporter occupancy

  2006cited by this paper
• Desvenlafaxine Succinate: A New Serotonin and Norepinephrine Reuptake Inhibitor

  2006cited by this paper
• Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography.

  2006cited by this paper
• Blood‐brain barrier‐specific properties of a human adult brain endothelial cell line

  2005cited by this paper
• ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier.

  2005cited by this paper
• THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL

  2005cited by this paper
• Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: a SPECT validation study

  2005cited by this paper
• The Pharmacokinetics of Escitalopram After Oral and Intravenous Administration of Single and Multiple Doses to Healthy Subjects

  2005cited by this paper
• Synthesis and characterization of EADAM: a selective radioligand for mapping the brain serotonin transporters by positron emission tomography.

  2005cited by this paper
• Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

  2004cited by this paper
• High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography.

  2003cited by this paper
• abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice.

  2003cited by this paper
• Synthesis and characterization of iodine-123 labeled 2beta-carbomethoxy-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane. A ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography.

  2003cited by this paper
• The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors.

  2003cited by this paper
• Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption.

  2003cited by this paper
• Dipyridamole enhances digoxin bioavailability via P‐glycoprotein inhibition

  2003cited by this paper
• Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors.

  2002cited by this paper
• Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P‐glycoprotein

  2002cited by this paper
• MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.

  2002cited by this paper
• MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males.

  2002cited by this paper
• The effects of the human MDR1 genotype on the expression of duodenal P‐glycoprotein and disposition of the probe drug talinolol

  2002cited by this paper
• Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus

  2001cited by this paper
• Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine.

  2001cited by this paper
• Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene.

  2001cited by this paper
• MDR1 Genotype-Related Pharmacokinetics of Digoxin After Single Oral Administration in Healthy Japanese Subjects

  2001cited by this paper
• Effect of grapefruit juice on digoxin pharmacokinetics in humans

  2001cited by this paper
• Comparative Studies on in Vitro Methods for Evaluating in Vivo Function of MDR1 P-Glycoprotein

  2001cited by this paper
• Identification of functionally variant MDR1 alleles among European Americans and African Americans

  2001cited by this paper
• Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver.

  2001cited by this paper
• Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.

  2000cited by this paper
• Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.

  2000cited by this paper
• OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.

  1999cited by this paper
• P-Glycoprotein, a gatekeeper in the blood-brain barrier.

  1999cited by this paper
• Fluoxetine Bioequivalence Study: Quantification of Fluoxetine and Norfluoxetine by Liquid Chromatography Coupled to Mass Spectrometry

  1999cited by this paper
• Pharmacokinetics of Sertraline and its N-Demethyl Metabolite in Elderly and Young Male and Female Volunteers

  1997cited by this paper
• Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites.

  1997cited by this paper
• Pharmacological profile of antidepressants and related compounds at human monoamine transporters.

  1997cited by this paper
• Simplified reference tissue model for PET receptor studies.

  1996cited by this paper
• Pharmacological characterization of the cloned human 5-hydroxytryptamine transporter.

  1996cited by this paper
• Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver.

  1995cited by this paper
• Methyl 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylate in vitro binding to dopamine and serotonin transporters under "physiological" conditions.

  1994cited by this paper
• Methyl 3β‐(4‐[125I]Iodophenyl)Tropane‐2β‐Carboxylate In Vitro Binding to Dopamine and Serotonin Transporters Under “Physiological” Conditions

  1994cited by this paper
• BLOOD BINDING AND TISSUE UPTAKE OF DRUGS. RECENT ADVANCES AND PERSPECTIVES

  1988cited by this paper
• A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography

  1984cited by this paper

• A Translational Model‐Based Meta‐Analysis to Predict Tremor Incidence Associated with Serotonin Reuptake Transporter Inhibition

  2025cites this paper
• Differentiated HT22 cells as a novel model for in vitro screening of serotonin reuptake inhibitors

  2023cites this paper
• Diminished responses to monoaminergic antidepressants but not ketamine in a mouse model for neuropsychiatric lupus

  2018cites this paper
• Investigation into the molecular mechanisms of the norepinephrine and serotonin transporters in Attention Deficit/Hyperactivity Disorder

  2018cites this paper